DOAC Reversal

Clinical meaning

Direct oral anticoagulants (DOACs) include factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and the direct thrombin (factor IIa) inhibitor dabigatran. Unlike warfarin, DOACs have predictable pharmacokinetics that typically do not require routine laboratory monitoring. However, when life-threatening bleeding or emergent surgery occurs, rapid reversal is critical.

Dabigatran reversal: Idarucizumab (Praxbind) is a humanized monoclonal antibody fragment (Fab) that binds dabigatran with ~350 times greater affinity than thrombin, effectively neutralizing ALL circulating dabigatran within minutes. Dose: 5 grams IV (two 2.5g vials) administered as two consecutive infusions. The RE-VERSE AD trial demonstrated complete reversal in 88% of patients within 4 hours. Idarucizumab is SPECIFIC to dabigatran — it does NOT reverse factor Xa inhibitors.

Factor Xa inhibitor reversal: Andexanet alfa (Andexxa) is a modified recombinant factor Xa decoy protein that binds and sequesters factor Xa inhibitors (rivaroxaban, apixaban, and LMWH). It has no intrinsic procoagulant activity because the active site serine has been replaced with alanine. Dosing depends on the specific Xa inhibitor and time since last dose (low-dose vs. high-dose regimen). The ANNEXA-4 trial showed hemostatic efficacy in ~82% of patients. Andexanet alfa carries a 10% risk of thrombotic events within 30 days.

Four-factor prothrombin complex concentrate (4F-PCC, e.g., KCentra): contains vitamin K-dependent coagulation factors II, VII, IX, X plus proteins C and S. Used as a non-specific reversal agent when specific antidotes are unavailable or when andexanet alfa is not accessible. Dose for DOAC reversal: 25-50 units/kg IV. Works within 15-30 minutes. Used off-label for factor Xa inhibitor reversal and is significantly less expensive than andexanet alfa.

Diagnosis & workup

Diagnostics & workup: - DOAC-specific drug levels (anti-Xa assay for rivaroxaban/apixaban, dilute thrombin time or ecarin clotting time for dabigatran): provide quantitative measurement of drug effect; most useful for determining if clinically significant drug levels are present before surgery or during bleeding - PT/INR: prolonged by rivaroxaban (dose-dependent) but UNRELIABLE for apixaban (minimally affected even at therapeutic levels); NOT useful for dabigatran (variable effect); PT/INR should NOT be used to guide DOAC management — a normal PT does NOT exclude DOAC effect - aPTT: prolonged by dabigatran (dose-dependent but saturates at supratherapeutic levels); less reliably affected by factor Xa inhibitors; a NORMAL aPTT generally excludes clinically significant dabigatran levels - Thrombin time (TT): EXTREMELY sensitive to dabigatran — a normal TT effectively excludes any clinically significant dabigatran presence; useful as a qualitative screen ('is dabigatran present or not?') - CBC with hemoglobin: quantify blood loss severity; trend hemoglobin every 4-6 hours during active bleeding; type and crossmatch for transfusion preparedness - Renal function (eGFR): CRITICAL for dabigatran (80% renal clearance — impaired clearance prolongs drug effect and time to spontaneous resolution); less critical but still relevant for rivaroxaban and edoxaban - Coagulation panel (PT/INR, aPTT, fibrinogen, D-dimer): establish baseline; fibrinogen <150 mg/dL may indicate consumptive coagulopathy; D-dimer elevation may suggest underlying DIC complicating the clinical picture

Risk factors: - Life-threatening hemorrhage on DOAC therapy: intracranial hemorrhage (highest mortality), GI hemorrhage (most common major bleed), retroperitoneal hemorrhage, intraocular hemorrhage - Emergency surgery or invasive procedure requiring immediate hemostasis in a patient who received DOAC within the past 24-48 hours (drug still active) - Renal impairment prolonging DOAC half-life: dabigatran is 80% renally cleared (t½ doubles from 12-17h to 28h with eGFR <30); rivaroxaban and apixaban have lesser renal dependence (33% and 27% renal clearance respectively) - Drug interactions increasing DOAC levels: strong CYP3A4 AND P-glycoprotein inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) increase rivaroxaban and apixaban levels; P-gp inhibitors alone increase dabigatran levels - Elderly patients (≥75 years): reduced renal clearance, lower body weight, increased fall risk — higher bleeding rates across all DOAC trials - Concurrent antiplatelet therapy: dual therapy (DOAC + aspirin) or triple therapy (DOAC + aspirin + P2Y12 inhibitor) markedly increases bleeding risk - Non-adherence with dose adjustments: failure to reduce doses for renal impairment (dabigatran 75 mg BID with eGFR 15-30), age/weight/creatinine criteria (apixaban 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5)

Clinical meaning

Your next step on FNP

Practice this topic

Review related lessons

FNP CAT

Diagnosis & workup

Management

Prescribing & monitoring

Takeaways

Your next step on FNP

Practice this topic

Review related lessons

FNP CAT

Clinical meaning

Practice questions for this topic

Your next step on FNP

Practice this topic

Review related lessons

FNP CAT

Diagnosis & workup

Practice questions for this topic

Your next step on FNP

Practice this topic

Review related lessons

FNP CAT